Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226721 | 1.00 | KMT2A (0.55) | KMT2AMEN1TP53NPC1RAB9A | |
| SCHEMBL4231330 | 0.92 | MAPT (0.60) | KMT2AMEN1TP53NPC1RAB9A | |
| SCHEMBL4237328 | 0.92 | MAPT (0.60) | KMT2AMEN1TP53NPC1RAB9A | |
| SCHEMBL4237326 | 0.92 | MAPT (0.60) | KMT2AMEN1TP53NPC1RAB9A | |
| SCHEMBL4228881 | 0.88 | KMT2A (0.57) | KMT2AMEN1TP53NPC1RAB9A | |
| SCHEMBL4228515 | 0.84 | TP53 (0.51) | KMT2AMEN1TP53RAB9AMAPT | |
| SCHEMBL4228514 | 0.84 | TP53 (0.51) | KMT2AMEN1TP53RAB9AMAPT | |
| SCHEMBL13911552 | 0.80 | OPRK1 (0.46) | HSD17B10KDM4EOPRK1 | |
| SCHEMBL4232683 | 0.80 | OPRK1 (0.46) | HSD17B10KDM4EOPRK1 | |
| SCHEMBL4232681 | 0.80 | OPRK1 (0.46) | HSD17B10KDM4EOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076064-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2007078251-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076064-A1 | Compounds | CEL, PLA2G2D, CCKBR | KMT2A 3907/4885MEN1 1092/4885TP53 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.